商品编号


AG-40T-0408-C100



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

100 ?g

商品信息


More Information



Product Details



Synonyms

Ubiquitin-conjugating Enzyme E2 I; p18; SUMO-protein Ligase; Ubc9; UBCE9; Ubiquitin-protein Ligase I; UBE2I



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human Ubc9 (Accession Nr. P63279).



Crossreactivity

Human



MW

~20kDa



Purity

≥95% (SDS-PAGE)



Formulation

Liquid. In 50mM HEPES pH 7.5, 100mM NaCl, 10% Glycerol (v/v), 1mM TCEP.



Other Product Data


Use:
Member of the SUMO?conjugating (E2) enzyme family that receives SUMO from a SUMO?activating (E1) enzyme and subsequently conjugates SUMO to substrate proteins. A SUMO ligase (E3) is sometimes utilized for SUMO conjugation, but is not always required. Reaction conditions will need to be optimized for each specific application. We recommend an initial protein concentration of 0.1-1μM.



Declaration

Manufactured by Boston Biochem



Shipping and Handling



Shipping

DRY ICE



Short Term Storage

-20°C



Long Term Storage

-80°C



Handling Advice

Aliquot to avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -80°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Ubiquitin-conjugating Enzyme E2I (UBE2I), also known as ubiquitin-conjugating enzyme 9 (Ubc9), is a ubiquitously expressed protein with a predicted molecular weight of 20 kDa. Human UBE2I/Ubc9 shares 100% amino acid sequence identity with the mouse and rat orthologs. UBE2I/Ubc9 catalyzes the addition of the ubiquitin-like protein SUMO to target proteins. SUMO is transferred from a ubiquitin-like activating (E1) enzyme heterodimer consisting of SAE1 and UBA2 to Cys93 of UBE2I/Ubc9. In contrast to most ubiquitin-conjugating (E2) enzymes that function in a complex with ubiquitin ligases (E3s), UBE2I/Ubc9 can interact directly with protein substrates and may also play a role in substrate recognition. UBE2I/Ubc9 mediates the SUMOylation of a variety of proteins including RanGAP1, HDAC4 and PML. Post-translational modifications of UBE2I/Ubc9, such as auto-SUMOylation at Lys14 or Ser71 phosphorylation by CDC2/CDK1, alter UBE2I/Ubc9 catalytic activity and target protein recognition. UBE2I/Ubc9-dependent SUMOylation reduces the levels of the stem cell
Marker
Nanog, implicating it in embryonic stem cell pluripotency maintenance. SUMOylation also regulates the protein levels of tumor suppressors and oncogenes, and UBE2I/Ubc9 dysregulation is thought to contribute to the pathogenesis of human cancers.